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THE ROLE OF CYTOTOXIC T CELL ANTIGEN-2 (CTLA2) IN MOUSE
HEMATOPOIETIC STEM CELL (HSC) TRANSPLANT ENGRAFTMENT AND
RECONSTITUTION EXAMINED BY LENTIVIRAL VECTOR TRANSDUC-
TION
Yankelevich, M.1, Volonakis, E.2, Goodell, M.A.2 1. Baylor College of
Medicine/ Texas Children’s Cancer Center, Houston, TX; 2. Baylor
College of Medicine/ Center for Cell and Gene Therapy, Houston, TX.
HSCs are rare cells resident in the bone marrow. HSCs must be
capable of robust proliferation and self-renewal. The regulation of
HSC proliferation occurs at least partly through interactions with
the microenvironment, or niche. We found that in contrast to
other bone marrow cells, HSCs constitutively express high levels of
CTLA2, and that after treatment with 5-FU, CTLA2 is down-
regulated in HSCs. We hypothesize that interaction between ca-
thepsin L and the endogenous cathepsin L inhibitor CTLA2 reg-
ulates interaction of HSCs with the quiescent niche. In this study,
bone marrow cells from 5-FU treated mice were transduced with
lentiviral vectors encoding ﬁve different transgenes (CTLA2
 and
 expression constructs, siRNA CTLA2
 and 
/ knockdown
constructs, and empty construct) and were transplanted into le-
thally irradiated mice with unmanipulated competitors. The short-
term, long-term, and lineage engraftment of transduced HSCs was
studied. Peripheral blood analysis at 4 weeks after transplant dem-
onstrated that 90 to 100% of the animals transplanted with empty
and CTLA2 knockdown constructs engrafted as oppose to 0 to
25% of the mice transplanted with CTLA2 expression transgenes.
The mean percentage of peripheral blood leukocytes derived from
the lentivirally transduced cells at 4 weeks post-transplant was 17%
for empty construct, 19% for CTLA2
/ knokdown construct,
6% for CTLA2
 knockdown construct, 1.5% for CTLA2
 ex-
pression construct, and 0% for CTLA2 expression construct. The
differences between empty and knockdown versus expression con-
structs were statistically signiﬁcant. When the analysis was re-
peated at 8 weeks post-transplant, the same result was observed.
Next, we did lineage distribution analysis of engrafted populations
at 	12 weeks post-transplant. We did not ﬁnd signiﬁcant differ-
ence between the distribution of granulocytes, T cells, and B cells
within peripheral blood leukocytes derived from engrafted popu-
lations when compared to untransduced cells. Thus, our prelimi-
nary ﬁndings demonstrated that HSCs transduced with CTLA2
over expression lentiviral constructs have inferior ability to engraft
(or may be impaired multilineage reconstitution?) compared to
empty and CTLA2 knockdown constructs. In the future, we plan
to study biological responses of modiﬁed HSCs to cytotoxic and
mobilization stimuli in vivo.
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EXPANSION OF UMBILICAL CORD BLOOD DERIVED OLIGODENDRO-
CYTES
Beam, D.T.1, Thacker, J., Kurtzberg, J.1 Duke University Medical
Center, Durham, NC.
Transplantation of children with lysosomal storage diseases
(LSD) with unrelated donor-umbilical cord blood (UCB) is effec-
tive in preventing onset and progression of severe neurologic
symptoms if performed early in the course of the disease. Unfor-
tunately, many children are not diagnosed before moderate to
severe neurologic damage has occurred. These symptomatic chil-
dren experience disease stabilization after transplant but do not
regain lost function. This may be due to the fact that irreversible
damage has occurred or, conversely, that stem cells transit to the
brain too slowly to effect neural cell repair. To address this prob-
lem, we have developed in vitro methods to isolate and characterize
oligodendrocytes derived from human UCB. We previously de-
scribed these methods and the initial characterization of these cells
(Hall et al). Continuing to advance this work, we now are focusing
on further characterization and expansion of this population of
cells in preparation for a phase I human clinical trial in patients
with symptomatic LSD. Human UCB is red cell depleted with
hetastarch, mononuclear cells are isolated with ﬁcol density sepa-
ration, and plated at a density of 5  105 cells/ml in media
containing neurotropin 3, vascular endothelial growth factor, and
platelet derived growth factor. The adherent cells are washed 2
per week for 2 weeks, then passaged and replated at a density of 5
103 cells/ml with media changes twice weekly, once with the
original oligodendrocyte media and the second with NeuroCult
media (StemCell Technologies, Vancouver). Cells expand with an
approximate doubling time of 6.5 days. After 4 and 6 week periods,
a 16- and 64-fold expansion can be seen, respectively. We antici-
pate that using a 20% fraction (200 106 cells) of a cord blood unit
we can obtain 33  108 cells in 6 weeks. Oligodendrocyte lineage
identity of these cells, post expansion, was conﬁrmed by PCR based
methods with expression of myelin basic protein, nestin, PLP, and
Neurogenin 3. We conclude that oligodendrocytes can be isolated
and expanded from human UCB yielding sufﬁcient numbers of
cells for testing in phase I human trials to facilitate neural cell
repair in patients with advanced LSD.
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OPTIMUM TEMPERATURE FOR MAINTAINING THE VIABILITY OF
CD34 CELLS DURING STORAGE AND TRANSPORT OF FRESH HAEMA-
TOPOIETIC PROGENITOR CELLS
Antonenas, V.1, Garvin, F.1, Sartor, M.1, Bradstock, K.1, Gottlieb, D.1
Sydney Cellular Therapies Laboratory, Westmead Hospital, Sydney,
NSW, Australia.
The optimum conditions for storage and transport of freshly
harvested hemopoietic progenitor cells (HPC) in the liquid state is
uncertain. It is not speciﬁed in commonly applied standards for
stem cell transplantation. We used a viable CD34 assay to deter-
mine the optimum temperature for maintaining progenitor cell
viability in freshly harvested bone marrow and peripheral blood
stem cells. Our aim was to identify standardized conditions for
storage and transport of marrow or peripheral blood products that
would optimize CD34 recovery leading to better transplant out-
comes. Samples were aseptically removed from 46 fresh HPC
harvests (34 PBSC and 12 BM) and stored at refrigerated temper-
ature (2°–8° C), room temperature (18°–24° C) and 37° C, for up
to 72 hours. Samples were analysed for viable CD34 cells/ml at
0, 24, 48, and 72 hours.
The mean viable CD34 yield prior to storage was 7.7 106/Kg
(range 0.7–30.3). The mean loss of viable CD34 cells in HPC
products at refrigerated temperature was 9.4%, 19.4%, and 28% at
24, 48, and 72 hours, respectively. In contrast, the mean loss of
viable CD34 cells at room temperature was 21.9%, 30.7%, and
43.3% at 24, 48, and 72 hours, respectively. No viable CD34
cells remained after storage at 37° C for 24 hours. Only PBSC
products and not BM showed temperature related loss of CD34
viability. Greater loss of viable CD34 cells was observed for
allogeneic PBSC compared to autologous PBSC. These results
demonstrate that the optimum temperature to maintain the viabil-
ity of CD34 cells during overnight storage and transport of
freshly harvested HPC is 2°–8° C. These ﬁndings allow for the
development of standard guidelines for HPC storage and trans-
port.
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DIFFUSE ALVEOLAR HEMORRHAGE (DAH) AND INFECTION ASSOCI-
ATED ALVEOLAR HEMORRHAGE (IAH) FOLLOWING HEMATOPOIETIC
STEM-CELL TRANSPLANTATION: RELATED AND HIGH RISK CLINICAL
SYNDROMES WITH POOR RESPONSE TO HIGH-DOSE CORTICOSTE-
ROIDS
Majhail, N.S.1, Parks, K.A.1, Defor, T.E.1, Weisdorf, D.J.1 Blood and
Marrow Transplant Program, University of Minnesota, Minneapolis,
MN.
Diffuse alveolar hemorrhage (DAH) is a non-infectious pul-
monary complication of hematopoietic stem-cell transplanta-
tion (HSCT) and is associated with signiﬁcant mortality. The
pathogenesis and treatment of DAH is unclear. We reviewed
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